F10 and intracranial hemorrhage: A 2019 retrospective, single-center study by Ammar and colleagues evaluated outcomes of andexanet alfa and 4FPCC in adult patients admitted with a life-threatening traumatic or spontaneous intracranial hemorrhage in the setting of factor Xa inhibitor therapy [9].